FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to application of compound 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydroimidazo[4,5-c]quinolin-1-yl)phenyl]propionitryl (compound A) or its pharmaceutically acceptable salt for obtaining pharmaceutical preparation, intended for treatment of disease, depending on epidermal growth factor receptor (EGFR), connected with EGFR amplification, EGFR1 mutation, T790M EGFR mutation, or their combination. Invention also relates to combinations of said compound with other active compounds and to methods of treating said diseases with said compounds and pharmaceutical preparations. Pharmaceutical preparations include said compound alone or in combination with, first of all, EGFR modulator.
EFFECT: application of combinations provides synergetic effect.
16 cl, 6 dwg
| Title |
Year |
Author |
Number |
| USING PYRIMIDINE DERIVATIVES FOR TREATING EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS AGAINST EGFR FAMILY |
2009 |
- Garsia-Ehcheverria Karlos
- Maira Sove-Mishel'
|
RU2496500C2 |
| USE OF 2-CARBOXAMIDE-CYCLOAMINO UREA DERIVATIVES IN TREATMENT OF EGFR-DEPENDENT DISEASES OR DISEASES WITH ACQUIRED RESISTANCE TO AGENTS TARGETED AT EGFR-FAMILY MEMBERS |
2011 |
- Brakhmann, Zaskia Mariya
- Fritch, Kristin
- Mera, Saver-Mishel
- Shnell, Kristian Rene
- Garsiya-Echeverriya, Karlos
|
RU2589695C2 |
| METHOD OF TREATING CANCER CARRYING EGFR MUTATIONS |
2007 |
|
RU2492864C2 |
| TETRAHYDROFOLATES IN COMBINATION WITH EGFR INHIBITORS |
2013 |
- Gustavsson Bengt
- Karlsson Bern
|
RU2619335C2 |
| SELECTIVE INHIBITOR OF EGFR HAVING MUTATION IN EXON 18 AND/OR EXON 21 |
2018 |
- Abe, Naomi
- Hasako, Shinichi
|
RU2785657C2 |
| COMBINATION OF EGFR INHIBITOR AND MEK INHIBITOR FOR USE IN TREATMENT OF NRAS MUTATED CANCER |
2015 |
- Cross Darren Anthony Edward
- Eberlein Catherine Anne
|
RU2683276C2 |
| SELECTIVE EGFR MUTANT INHIBITOR WITH INSERTION IN EXON 20 |
2017 |
- Miyadera, Kazutaka
- Aoyagi, Yoshimi
- Hasako, Shinichi
|
RU2774629C2 |
| COMBINED C-MET AND EGFR ANTAGONISTS THERAPY |
2009 |
- Filvaroff Ellen
- Merchant Mark
- Josh Robert L.
|
RU2601892C2 |
| EGFR INHIBITOR COMPOUNDS |
2017 |
- Banker, Kevin Duejn
- Khuan, Piter Tsinkhua
- Abrakham, Sanni
- Pinchman, Dzhozef Robert
- Khopkins, Chad Deniel
- Sli, Debora Khelen
|
RU2751341C2 |
| NEW COMBINATION OF 3-[(3-{[4-(4-MORPHOLINYLMETHYL)-1N-PYRROL-2-YL]METHYLENE}-2-OXO-2,3-DIHYDRO-1N-INDOL-5-YL)METHYL]-1,3-THIAZOLIDINE-2,4-DIONE AND TYROSINE KINASE INHIBITOR EGFR |
2016 |
- Berbridzh Majkl
- Kattan Valeri
- Zhak-Beskon Anne
|
RU2695362C2 |
